TruSight Tumor 170

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

• Comprehensive Coverage of Cancer-Related Variants
  Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
• Accurate Results from Low-Quality Samples1
  Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
• Integrated, Streamlined Workflow
  DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis

TruSight Tumor 170 Data Sheet | PDF(< 1 MB)

Visit    Web Site...